IL13 and neoplasm: These cell types have previously been shown to either promote or hinder anti-tumor immunity depending on their cytokine production profile, with type I NKTs producing IFNγ to recruit NK cells and activate DCs [74], whereas Type II NKTs produce IL-13 and TGF-β that suppress anti-tumor immunity [75,76].